Skip to main content
    M

    Monte Rosa Therapeutics Inc (GLUE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.16
    -0.21 (-2.24%)

    Market Cap: $800.67M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Monte Rosa Therapeutics Inc (GLUE) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Monte Rosa Therapeutics (GLUE) trades at 13.3x sales and 1.9x book value. Its P/B of 1.9x is above its 5-year median of 1.7x. Its forward P/E is 10.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E10.0x
    Price to sales13.3x
    Price to book1.9x
    PEGN/A
    FCF yield-18.7%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/B1.9x1.7xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 3 of the 5 year ends shown that have a P/S, its P/S ranged from 5.9x in 2024 to 36.8x in 2023.

    Year endPriceP/SP/B
    2025$15.6810.4x4.4x
    2024$6.945.9x1.9x
    2023$5.6536.8x1.8x
    2022$7.61N/A1.4x
    2021$20.42N/A2.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About GLUE

    What is GLUE's forward P/E ratio?

    Monte Rosa Therapeutics has a forward P/E ratio of 10.0x.

    Is GLUE stock overvalued?

    GNG's valuation label for GLUE is Overvalued.

    What is GLUE's price to sales ratio?

    Monte Rosa Therapeutics has a price to sales ratio of 13.3x.